Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2020–2024

EDUC8 · Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2020-04-01 → 2024-09-30
EU contribution
€2,100,702
Participants
9
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity

The development of anti-drug antibodies is the major complication of treatment with biotherapeutics. This is particularly true of patients with haemophilia A (HA) who develop neutralizing antibodies to therapeutic factor VIII (FVIII) following replacement therapy with exogenous pro-coagulant FVIII. The onset of neutralizing antibodies to FVIII, referred to as FVIII inhibitors, represents a major societal concern owing to the enormous cost associated to the clinical management of inhibitor-positive patients, that exceeds 200,000€/patient/year. The EDUC8 program is a multidisciplinary training program with exposure of the enrolled ESRs to a core common educational package and development of individual PhD research projects dedicated to decreasing the societal burden associated with the development of anti-FVIII antibodies in Europe. The core educational program included exposure to basic science in the fields of immunology and hemostasis, to the most advanced “omic” technologies in order to anticipate tomorrow’s scientific discoveries, and to the importance of ethical considerations and public awareness in today’s research. A key component of the training program was provided by immersion of the ESRs in a clinical center for HA, which provided them with a unique experience and foster the conception of novel and realistic therapeutic approaches. The ESRs exploited the accumulated theoretic and practical experience in an entrepreneurship training on key strategic, technical, financial and human resource issues required for the creation of startups. In a tribute to the concept of the fully developed mind coined by the French philosopher Michel de Montaigne on education, our ambition has been to form a novel generation of scientists with deep scientific knowledge, multicultural exposure, imagination, pragmatism and understanding of both the academic and private sectors. This shall foster translational research in European on the immunogenicity of therapeutic proteins.

Data: CORDIS, © European Union

Project objective

The development of anti-drug antibodies is the major complication of treatment with biotherapeutics. This is particularly trueof patients with haemophilia A (HA) who develop neutralizing antibodies to therapeutic factor VIII (FVIII) followingreplacement therapy with exogenous pro-coagulant FVIII. The onset of neutralizing antibodies to FVIII, referred to as FVIIIinhibitors, represents a major societal concern owing to the enormous cost associated to the clinical management ofinhibitor-positive patients, that exceeds 200,000€/patient/year. The EDUC8 program is a multidisciplinary training programwith exposure of the enrolled ESRs to a core common educational package and development of individual PhD researchprojects dedicated to decreasing the societal burden associated with the development of anti-FVIII antibodies in Europe. Thecore educational program includes exposure to basic science in the fields of immunology and hemostasis, to the mostadvanced “omic” technologies in order to anticipate tomorrow’s scientific discoveries, and to the importance of ethicalconsiderations and public awareness in today’s research. A key component of the training program is provided by immersionof the ESRs in a clinical center for HA, which will provide them with a unique experience and foster the conception of noveland realistic therapeutic approaches. The ESRs will exploit the accumulated theoretic and practical experience in anentrepreneurship training on key strategic, technical, financial and human resource issues required for the creation of startups.In a tribute to the concept of the fully developed mind coined by the French philosopher Michel de Montaigne oneducation, our ambition is to form a novel generation of scientists with deep scientific knowledge, multicultural exposure,imagination, pragmatism and understanding of both the academic and private sectors. This will foster translational research in European on the immunogenicity of therapeutic proteins.

Original text from CORDIS.

Participants

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisCoordinatorFrance
  • COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · ParisFrance
  • DC4U · BreukelenNetherlands
  • JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainGermany
  • STICHTING AMSTERDAM UMC · AmsterdamNetherlands
  • Stichting Sanquin Bloedvoorziening · AmsterdamNetherlands
  • TOPAS THERAPEUTICS GMBH · HAMBURGGermany
  • UNIVERSITA DEGLI STUDI DI MILANO · MilanoItaly
  • UNIVERSITATSKLINIKUM BONN · BonnGermany

Links

Data: CORDIS, © European Union